Compare · NVO vs TLSA
NVO vs TLSA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Tiziana Life Sciences Ltd. (TLSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TLSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1525.3x TLSA ($141.3M).
- Both names hit the wire about 9 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for TLSA).
- Company
- Novo Nordisk A/S
- Tiziana Life Sciences Ltd.
- Price
- -
- -
- Market cap
- $215.46B
- $141.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 9
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Tiziana Life Sciences Ltd.
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TLSA
- SEC Form 6-K filed by Tiziana Life Sciences Ltd.
- Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
- Amendment: Director Cerrone Gabriele M bought $41,933 worth of shares (42,357 units at $0.99) (SEC Form 4)
- Amendment: Director Cerrone Gabriele M bought $16,650 worth of shares (15,000 units at $1.11) (SEC Form 4)
- Chief Executive Officer Elrifi Ivor bought $318,909 worth of shares (321,423 units at $0.99) (SEC Form 4)
- SEC Form 6-K filed by Tiziana Life Sciences Ltd.
- Chief Executive Officer Elrifi Ivor bought $667,000 worth of shares (667,000 units at $1.00) (SEC Form 4)
- SEC Form 6-K filed by Tiziana Life Sciences Ltd.
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
- SEC Form 6-K filed by Tiziana Life Sciences Ltd.